← Eichor
Study identifier: NCT04293562 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Condition: Acute Myeloid Leukemia  ·  Sponsor: Children's Oncology Group

PhasePhase 3
Planned participants1186
Who can joinAll sexes, N/A to 21 Years
Healthy volunteersNo

About this study

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or b…

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (205)

Children's Hospital of AlabamaBirmingham, Alabama, United StatesRecruiting
USA Health Strada Patient Care CenterMobile, Alabama, United StatesRecruiting
Banner Children's at DesertMesa, Arizona, United StatesRecruiting
Phoenix Childrens HospitalPhoenix, Arizona, United StatesRecruiting
Banner University Medical Center - TucsonTucson, Arizona, United StatesRecruiting
Arkansas Children's HospitalLittle Rock, Arkansas, United StatesRecruiting
Kaiser Permanente Downey Medical CenterDowney, California, United StatesRecruiting
City of Hope Comprehensive Cancer CenterDuarte, California, United StatesRecruiting
Loma Linda University Medical CenterLoma Linda, California, United StatesRecruiting
Miller Children's and Women's Hospital Long BeachLong Beach, California, United StatesRecruiting
Children's Hospital Los AngelesLos Angeles, California, United StatesRecruiting
Cedars-Sinai Medical CenterLos Angeles, California, United StatesRecruiting

+ 193 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04293562